<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04188639</url>
  </required_header>
  <id_info>
    <org_study_id>AHA-EMI (MO41153)</org_study_id>
    <nct_id>NCT04188639</nct_id>
  </id_info>
  <brief_title>Emicizumab in Acquired Hemophilia A</brief_title>
  <official_title>Emicizumab in Patients With Acquired Hemophilia A: Multicenter, Single-arm, Open-label Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GWT-TUD GmbH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hannover Medical School</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>GWT-TUD GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is an international, multicenter, open-label, single arm, prospective clinical&#xD;
      trial and will evaluate the efficacy of prophylactic emicizumab administered on a scheduled&#xD;
      basis to prevent bleeds in patients with acquired hemophilia A (AHA).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 23, 2021</start_date>
  <completion_date type="Anticipated">September 2024</completion_date>
  <primary_completion_date type="Anticipated">September 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The number of clinically significant bleeds per patient-week until death or week 12 after starting emicizumab treatment, whatever occurs first</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of adverse events, thromboembolic events, thrombotic microangiopathy in the 12 weeks after starting emicizumab</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of mortality and cause of death in the 24 weeks after starting emicizumab treatment</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days of treatment with and total dose of bypassing agents (recombinant factor VIIa, activated prothrombin complex concentrate) or recombinant porcine factor VIII (susoctocag alfa) or other factor VIII concentrates</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days in hospital during 12 weeks of emicizumab treatment</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients achieving partial remission in the 24 weeks after starting emicizumab treatment</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">51</enrollment>
  <condition>Hemophilia A, Acquired</condition>
  <arm_group>
    <arm_group_label>Treatment with emicizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Emicizumab Injection</intervention_name>
    <description>All eligible patients with AHA will receive the same study medication consisting of once weekly subcutaneous emicizumab. For each subject, the maximal duration of the study will be 24 weeks including 12 weeks treatment with emicizumab and 12 weeks Immunosuppressive therapy according to local standard of care.</description>
    <arm_group_label>Treatment with emicizumab</arm_group_label>
    <other_name>Hemlibra (R)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients diagnosed with AHA based on a reduced FVIII activity (&lt;50 %) and positive&#xD;
             FVIII inhibitor (&gt;0.6 BU/ml) at screening (local laboratory)&#xD;
&#xD;
          -  Signed informed consent form by the participant or a Person who is legally authorized&#xD;
             to sign on behalf of the participant before any study specific tests or procedures are&#xD;
             done&#xD;
&#xD;
          -  Male or female patients aged 18 years or older at the time of informed consent&#xD;
&#xD;
          -  Ability to understand and follow study-related instructions&#xD;
&#xD;
          -  Current bleeds due to AHA at the time of screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Congenital hemophilia A&#xD;
&#xD;
          -  Treatment with aPCC within the last 48 h before first study treatment or planned&#xD;
             treatment with aPCC during the course of the study&#xD;
&#xD;
          -  Treatment of AHA within the days before study enrollment with more than 100 mg&#xD;
             prednisolone (or equivalent) per day or prednisolone for more than 2 days or with&#xD;
             other immunosuppressive drugs (e.g. rituximab, cyclophosphamide). IST for other&#xD;
             concomitant disorders (e.g. autoimmune disorders) is not an exclusion criterion and&#xD;
             can be continued at the investigator's discr√©tion&#xD;
&#xD;
          -  Therapy (current or planned during the emicizumab treatment period) with&#xD;
             immunospuppressive or immune modulating drugs that were not already given on a regular&#xD;
             basis before first diagnosis of AHA&#xD;
&#xD;
          -  Positive lupus anticoagulant at the time of screening&#xD;
&#xD;
          -  Severe uncontrolled infection at the time of screening&#xD;
&#xD;
          -  Signs of active disseminated intravascular coagulation at the time of screening&#xD;
&#xD;
          -  Current treatment for thromboembolic disease or signs of current thromboembolic&#xD;
             disease at time of screening&#xD;
&#xD;
          -  Patients who are at high risk for TMA (e.g., have a previous medical or family history&#xD;
             of TMA), in the investigator's judgment&#xD;
&#xD;
          -  Known severe congenital or acquired thrombophilia&#xD;
&#xD;
          -  Life expectancy &lt;3 months at the time of screening&#xD;
&#xD;
          -  Other conditions that substantially increase risk of bleeding or thrombosis by the&#xD;
             discretion of the investigator&#xD;
&#xD;
          -  Contraindications according to the local SmPC of emicizumab (see 16.1 Appendix I)&#xD;
&#xD;
          -  Current treatment with emicizumab at time of screening&#xD;
&#xD;
          -  History of clinically significant hypersensitivity associated with monoclonal antibody&#xD;
             therapies or components of the emicizumab injection by the discretion of the&#xD;
             investigator&#xD;
&#xD;
          -  Concurrent disease, treatment, or abnormality in clinical laboratory tests that could&#xD;
             interfere with the conduct of the study, may pose additional risk, or would, in the&#xD;
             opinion of the local investigator, preclude the patient's safe participation in and&#xD;
             completion of the study&#xD;
&#xD;
          -  Addiction or other diseases that preclude the patient from appropriately assessing the&#xD;
             nature and scope as well as possible consequences of the clinical study by the&#xD;
             discretion of the investigator&#xD;
&#xD;
          -  Pregnant or breast-feeding women&#xD;
&#xD;
          -  Women of childbearing potential unless women who meet the following criteria:&#xD;
&#xD;
               1. Post-menopausal (12 months natural amenorrhea or 6 months amenorrhea with serum&#xD;
                  FSH &gt; 40 U/mL)&#xD;
&#xD;
               2. Postoperatively (six weeks after bilateral ovariectomy with or without&#xD;
                  hysterectomy)&#xD;
&#xD;
               3. Regular and correct use of a contraceptive method with error rate &lt;1% per year&#xD;
                  such as implants, depot injections, oral contraceptives or intrauterine devices&#xD;
&#xD;
               4. Sexual abstinence&#xD;
&#xD;
               5. Vasectomy of the partner&#xD;
&#xD;
          -  Men of sexual activity with women of childbearing potential who are not willing to use&#xD;
             an effective barrier method of contraception during and up to 3 months after the end&#xD;
             of therapy&#xD;
&#xD;
          -  Subject is in custody by order of an authority or a court of law&#xD;
&#xD;
          -  Receipt of an investigational drug concurrently or within 5 half-lives before&#xD;
             administration of the study drug&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andreas Tiede, Prof. Dr.</last_name>
    <role>Study Director</role>
    <affiliation>Hannover Medical School</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>GWT-TUD GmbH</last_name>
    <phone>+49 (0) 351 25933 100</phone>
    <email>medical.consulting@gwtonline.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Carmen Weigt, Dr.</last_name>
    <email>carmen.weigt@gwtonline.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>LMU Klinikum</name>
      <address>
        <city>M√ºnchen</city>
        <state>Bayern</state>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick M√∂hnle, PD Dr. med.</last_name>
      <phone>+49 89 4400 57696</phone>
      <email>patrick.moehnle@med.uni-muenchen.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universit√§tsklinikum Regensburg</name>
      <address>
        <city>Regensburg</city>
        <state>Bayern</state>
        <zip>93052</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christina Hart, PD Dr. med.</last_name>
      <phone>+49 (0) 941 944 5501</phone>
      <email>christina.hart@ukr.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vivantes Klinikum im Friedrichshain</name>
      <address>
        <city>Berlin-Friedrichshain</city>
        <state>Berlin</state>
        <zip>10249</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Klamroth, PD Dr. med.</last_name>
      <phone>+49 (0) 30 130 23 1575</phone>
      <email>robert.klamroth@vivantes.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universit√§tsklinikum Frankfurt</name>
      <address>
        <city>Frankfurt</city>
        <state>Hessen</state>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wolfgang Miesbach, Prof. Dr. med.</last_name>
      <phone>+49 (0) 69-6301 5051</phone>
      <email>wolfgang.miesbach@kgu.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <state>Niedersachsen</state>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susanne Bartels</last_name>
      <phone>+49(0) 511 532</phone>
      <phone_ext>3636</phone_ext>
      <email>tiede.clinical-trials@mh-hannover.de</email>
    </contact>
    <investigator>
      <last_name>Andreas Tiede, Prof. Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christiane Dobbelstein, Dr. med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universit√§tsklinikum des Saarlandes, Institut f√ºr Klinische H√§mostaseologie und Transfusionsmedizin</name>
      <address>
        <city>Homburg / Saar</city>
        <state>Saarland</state>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hermann Eichler, Prof. Dr. med.</last_name>
      <phone>+49 (0)6841 1622530</phone>
      <email>hermann.eichler@uks.eu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universit√§tsklinikum Dresden</name>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karolin Trautmann-Grill, Dr. med.</last_name>
      <phone>+49 351 458 2311</phone>
      <email>karolin.trautmann@ukdd.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universit√§tsklinikum Leipzig, Medizinische Klinik und Poliklinik I, Bereich H√§mostaseologie</name>
      <address>
        <city>Leipzig</city>
        <state>Sachsen</state>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Pfrepper, Dr. med.</last_name>
      <phone>+ 49 341 97 12700</phone>
      <email>christian.pfrepper@medizin.uni-leipzig.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universit√§tsklinikum Schleswig-Holstein</name>
      <address>
        <city>Kiel</city>
        <state>Schleswig-Holstein</state>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ulrike Nowak-G√∂ttl, Prof. Dr. med.</last_name>
      <phone>+49 (0) 431 500 16202</phone>
      <email>leagottl@uksh.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universit√§tsklinikum Jena, Klinik f√ºr Innere Medizin II</name>
      <address>
        <city>Jena</city>
        <state>Th√ºringen</state>
        <zip>07747</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Krisitna Schilling, Dr. med.</last_name>
      <phone>+49 (0) 3641 932 45 72</phone>
      <email>Kristina.Schilling@med.uni-jena.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>December 4, 2019</study_first_submitted>
  <study_first_submitted_qc>December 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 6, 2019</study_first_posted>
  <last_update_submitted>August 18, 2021</last_update_submitted>
  <last_update_submitted_qc>August 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>acquired Hemophilia A</keyword>
  <keyword>Factor VIII activity</keyword>
  <keyword>Emicizumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

